Form 8-K - Current report:
SEC Accession No. 0001641172-25-004599
Filing Date
2025-04-14
Accepted
2025-04-14 17:13:09
Documents
17
Period of Report
2025-04-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 75043
2 ex10-1.htm EX-10.1 339127
3 ex10-2.htm EX-10.2 323835
4 ex10-3.htm EX-10.3 174393
5 ex10-4.htm EX-10.4 87694
  Complete submission text file 0001641172-25-004599.txt   1389427

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE evfm-20250408.xsd EX-101.SCH 3009
7 XBRL LABEL FILE evfm-20250408_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE evfm-20250408_pre.xml EX-101.PRE 24161
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 25836751
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)